


Supplementary Materials A. Patient post-COVID-19 condition self-assessment scale



Supplementary Materials B. Study symptom coding

Study symptom coding	Definition of symptoms group
Smell and taste symptoms	Aguesia, anosmia
Other ear-nose-throat symptoms	Tinnitus, vestibular involvement, odynophagia, rhinorrhea, dysphagia or other otorhinolaryngologic symptoms
Asthenia	Asthenia or fatigue
Fevers or Shivering	Fevers or shivering
Cardiothoracic symptoms	Dyspnea, cough, thoracic pain and oppression, tachycardia, bradycardia or desaturation
Neurological and neurocognitive symptoms	
<i>Neurocognitive</i>	Concentration and attention disorders (bradypsychia), immediate memory disorders, insomnia/hypersomnia
<i>Sensory disorders</i>	Tingling, burning, neurogenic pain or balance disorders or paresthesia
<i>Other neurological</i>	Difficulty swallowing, difficulty articulating, urinary retention, thermoregulation disorders, deafness, dysphonia, thermoregulation
Psychic disorders	Anxiety, emotionality, thymic disorders, mood disorders
Digestive symptoms	Diarrhea, abdominal pain, constipation, gastroparesis or vomiting/nausea
Musculoskeletal	Myalgias, muscle weakness, arthralgias or tenosynovitis
Cutaneous and vascular symptoms	Urticaria, eczema, subcutaneous hematoma or vascular inflammation
Ophthalmic symptoms	Dry eyes, cloudy vision, conjunctivitis, orbit pain or visual blurring

Supplementary Materials C: Detail of symptoms by class between initial long COVID phase and one year follow-up

Symptoms	Initial long COVID -19 phase				One year follow-up			
	N	%	95% CI		N	%	95% CI	
Smell and taste	82	35.5%	29.3%	- 42.0%	92	39.8%	33.5%	- 46.5%
Ageusia	33	14.3%	10.0%	- 19.5%	63	27.3%	21.6%	- 33.5%
Anosmia	79	34.2%	28.1%	- 40.7%	80	34.6%	28.5%	- 41.2%
Other ear-nose-throat	53	22.9%	17.7%	- 28.9%	146	63.2%	56.6%	- 69.4%
Odynophagia or dysphagia	20	8.7%	5.4%	- 13.1%	61	26.4%	20.8%	- 32.6%
Tinnitus or vestibular involvement	37	16.0%	11.5%	- 21.4%	99	42.9%	36.4%	- 49.5%
Rhinorrhea	13	5.6%	3.0%	- 9.4%	54	23.4%	18.1%	- 29.4%
Asthenia	178	77.1%	71.1%	- 82.3%	192	83.1%	77.7%	- 87.7%
Fevers or Shivering	39	16.9%	12.3%	- 22.3%	75	32.5%	26.5%	- 38.9%
Cardiothoracic	187	81.0%	75.3%	- 85.8%	180	77.9%	72.0%	- 83.1%
Cough	36	15.6%	11.2%	- 20.9%	54	23.4%	18.1%	- 29.4%
Thoracic pain, chest tightness and tachycardia	155	67.1%	60.6%	- 73.1%	117	50.6%	44.0%	- 57.3%
Dyspnea	132	57.1%	50.5%	- 63.6%	142	61.5%	54.9%	- 67.8%
Other cardiothoracic	7	3.0%	1.2%	- 6.1%	38	16.5%	11.9%	- 21.9%
Neurological and neurocognitive	193	83.5%	78.1%	- 88.1%	212	91.8%	87.5%	- 95.0%
Neurocognitive	132	57.1%	50.5%	- 63.6%	174	75.3%	69.2%	- 80.7%
Sensory disorders	142	61.5%	54.9%	- 67.8%	190	82.3%	76.7%	- 87.0%
Other neurological	50	21.6%	16.5%	- 27.5%	91	39.4%	33.0%	- 46.0%
Psychic	36	18.7%	13.4%	- 24.9%	158	68.4%	62.0%	- 74.3%
Digestive	93	40.3%	33.9%	- 46.9%	124	53.7%	47.0%	- 60.2%
Diarrhea	56	24.2%	18.9%	- 30.3%	48	20.8%	15.7%	- 26.6%
Vomiting/Nausea	26	11.3%	7.5%	- 16.1%	47	20.3%	15.3%	- 26.1%
Other digestive	50	21.6%	16.5%	- 27.5%	104	45.0%	38.5%	- 51.7%
Musculoskeletal	93	40.3%	33.9%	- 46.9%	182	78.8%	72.9%	- 83.9%
Myalgias or muscle weakness	69	29.9%	24.0%	- 36.2%	122	52.8%	46.2%	- 59.4%
Arthralgias or tenosynovitis	51	22.1%	16.9%	- 28.0%	182	78.8%	72.9%	- 83.9%
Cutaneous and vascular	72	31.2%	25.3%	- 37.6%	142	61.5%	54.9%	- 67.8%
Urticaria or eczema	32	13.9%	9.7%	- 19.0%	60	26.0%	20.4%	- 32.1%
Subcutaneous hematoma or vascular inflammation	44	19.0%	14.2%	- 24.7%	82	35.5%	29.3%	- 42.0%
Other cutaneous	29	12.6%	8.6%	- 17.5%	90	39.0%	32.6%	- 45.6%
Ophthalmic	48	20.8%	15.7%	- 26.6%	103	44.6%	38.1%	- 51.2%

Supplementary D: Cumulative percentage of participants reporting symptom remission at one year

